Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.176
Neutral
RSI(14)
57.627
Neutral
STOCH(KDJ)(9,3,3)
70.294
Neutral
ATR(14)
0.885
Low Volatility
CCI(14)
6.503
Neutral
Williams %R
33.333
Buy
TRIX(12,20)
0.331
Sell
StochRSI(14)
0.000
Oversold
Search
Qiagen NV
QGENAdd to Watchlist
41.400USD
-0.050-0.12%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.54BMarket Cap
22.15P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.12%
5 Days
+0.07%
1 Month
+5.88%
6 Months
-22.86%
Year to Date
-8.09%
1 Year
-16.23%
Key Figures
41.140Open
41.570High
1.34MVolume
22.15P/E TTM
16.78P/E Dynamic
0.250Dividend TTM
0.62%Turnover Ratio
41.450Prev. Close
40.960Low
30.03MTurnover
107.25P/E Static
2.37P/B
0.60%Div Yield TTM
7.10%ROA
57.81552wk High
0.68Volume Ratio
83.59MNet Profit
216.56MShares
1.8687EPS TTM
0.66Beta
11.93%ROE
32.53052wk Low
1.47%Amplitude
62.41%Gross Margin
8.54BMarket Cap
1.73Reward/Risk
1.95%Risk Rate
TradingKey Stock Score of Qiagen NV
Currency: USD Updated: 2026-07-31Key Insights
Qiagen NV's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 27 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.10.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Qiagen NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Qiagen NV Highlights
StrengthsRisks
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.09B.
Undervalued
The company’s latest PE is 22.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.40M shares, decreasing 15.71% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 93.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.83.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
45.098
Target Price
+7.86%
Upside Space
Qiagen NV News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
16
analysts
Buy
Current Rating
45.098
Target Price
+7.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Qiagen NV
QGEN
16
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
41.604
Sell
MA10
41.242
Buy
MA20
40.934
Buy
MA50
38.664
Buy
MA100
38.480
Buy
MA200
43.152
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Qiagen NV Info
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Ticker SymbolQGEN
CompanyQiagen NV
CEOBernard (Thierry)
Websitehttps://www.qiagen.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Qiagen NV (QGEN)?
The current price of Qiagen NV (QGEN) is 41.42.
What is the symbol of Qiagen NV?
The ticker symbol of Qiagen NV is QGEN.
What is the 52-week high of Qiagen NV?
The 52-week high of Qiagen NV is 57.81.
What is the 52-week low of Qiagen NV?
The 52-week low of Qiagen NV is 32.53.
What is the market capitalization of Qiagen NV?
The market capitalization of Qiagen NV is 8.97B.
Is Qiagen NV (QGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Qiagen NV (QGEN) has an overall rating of Buy, with a price target of 45.10.
What is the Earnings Per Share (EPS TTM) of Qiagen NV (QGEN)?
The Earnings Per Share (EPS TTM) of Qiagen NV (QGEN) is 1.96.